MetaVia to Present at Upcoming Investor and Industry Conferences
26 augusti, 14:31
MetaVia to Present at Upcoming Investor and Industry Conferences
PR Newswire
CAMBRIDGE, Mass., Aug. 26, 2025
CAMBRIDGE, Mass. , Aug. 26, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences.
- September 3-5 : Wells Fargo Healthcare Conference. Hyung Heon Kim , President and Chief Executive Officer will attend this conference in Boston, Massachusetts .
- September 8-10 : H.C. Wainwright 27 th Annual Global Investment Conference. Mr. Kim will participate in fireside chat. The Company's on-demand presentation will be available to view beginning Friday, September 5, 2025 , at 7:00 am ET on the H.C. Wainwright Conference Portal and on the Event Calendar page of the MetaVia website https://ir.metaviatx.com/events-presentations/event-calendar .
Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company. - September 16-17 : Obesity Science & Innovation 2025 Congress. Mr. Kim will present a company overview with a focus on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity, at this conference in Boston, Massachusetts .
- October 7-9 : Fierce Biotech Week. Mr. Kim will attend this conference in Boston, Massachusetts .
To schedule a meeting with management outside of these events, investors can contact Michael Miller at mmiller@rxir.com .
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1 , GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com .
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
SOURCE MetaVia Inc.
MetaVia to Present at Upcoming Investor and Industry Conferences
26 augusti, 14:31
MetaVia to Present at Upcoming Investor and Industry Conferences
PR Newswire
CAMBRIDGE, Mass., Aug. 26, 2025
CAMBRIDGE, Mass. , Aug. 26, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences.
- September 3-5 : Wells Fargo Healthcare Conference. Hyung Heon Kim , President and Chief Executive Officer will attend this conference in Boston, Massachusetts .
- September 8-10 : H.C. Wainwright 27 th Annual Global Investment Conference. Mr. Kim will participate in fireside chat. The Company's on-demand presentation will be available to view beginning Friday, September 5, 2025 , at 7:00 am ET on the H.C. Wainwright Conference Portal and on the Event Calendar page of the MetaVia website https://ir.metaviatx.com/events-presentations/event-calendar .
Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company. - September 16-17 : Obesity Science & Innovation 2025 Congress. Mr. Kim will present a company overview with a focus on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity, at this conference in Boston, Massachusetts .
- October 7-9 : Fierce Biotech Week. Mr. Kim will attend this conference in Boston, Massachusetts .
To schedule a meeting with management outside of these events, investors can contact Michael Miller at mmiller@rxir.com .
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1 , GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com .
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
SOURCE MetaVia Inc.
Nvidia-rapporten
Analyser
PPM-upphandlingen
-950x950.webp&w=3840&q=75)
-992x558.webp&w=3840&q=75)
Nvidia-rapporten
Analyser
PPM-upphandlingen
Marknadsöversikt
1 DAG %
Senast
1 mån
.jpg&w=3840&q=75)
